- seekingalpha.com
- Posted On 15 November 2026
Novo Nordisk reports additional CagriSema weight-loss findings
Novo Nordisk (NVO) said two additional analyses of its late-stage REDEFINE 1 trial found differing weight-loss patterns and improvements in daily functioning am...
Source:
seekingalpha.com